COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
Demographic Details | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Male | 450 (67.7) | 745 (64.2) | 0.13 |
Indigenous | 46 (6.9) | 74 (6.4) | 0.87 |
Non-Indigenous | 404 (60.8) | 671 (57.8) | |
Female | 215 (32.3) | 416 (35.8) | 0.13 |
Indigenous | 59 (8.9) | 90 (7.8) | 0.10 |
Non-Indigenous | 156 (23.5) | 326 (28.1) |
Category of Admission | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Drug | 19 (17.1) | 16 (8.8) | 0.06 |
Male | 2 (4.3) | 9 (11.0) | 0.20 |
Female | 17 (26.6) | 7 (7.1) | <0.01 |
Infection | 19 (17.1) | 40 (22.1) | 0.29 |
Male | 6 (12.8) | 22 (26.8) | <0.05 |
Female | 13 (20.3) | 18 (18.2) | 0.84 |
Local wound infection | 6 (5.4) | 19 (10.5) | 0.13 |
Male | 1 (2.1) | 9 (11.0) | 0.09 |
Female | 5 (7.8) | 10 (10.1) | 0.78 |
Gastrointestinal | 16 (14.4) | 16 (8.8) | 0.18 |
Male | 9 (19.1) | 7 (8.5) | 0.17 |
Female | 7 (10.9) | 9 (9.1) | 0.79 |
Trauma | 24 (21.6) | 43 (23.8) | 0.56 |
Male | 6 (12.8) | 4 (4.9) | 0.18 |
Female | 18 (28.1) | 39 (39.4) | 0.12 |
Alcohol | 4 (3.6) | 12 (6.6) | 0.30 |
Male | 4 (8.5) | 6 (7.3) | 1.0 |
Female | 0 (0.0) | 6 (6.1) | 0.08 |
Others | 23 (20.7) | 35 (19.3) | 0.99 |
Male | 19 (40.4) | 25 (30.5) | 0.44 |
Female | 4 (6.3) | 10 (10.1) | 0.57 |
Admission Category | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Drug | 48 (8.1) | 135 (12.9) | <0.01 |
Male | 27 (6.3) | 87 (12.3) | <0.01 |
Female | 21 (12.5) | 48 (14.1) | 0.78 |
Infection * | 83 (13.9) | 117 (11.1) * | 0.08 |
Male | 56 (13.1) | 67 (9.4) † | 0.06 |
Female | 27 (16.1) | 50 (14.7) ‡ | 0.60 |
Wound infection | 29 (4.9) | 61 (5.8) | 0.50 |
Male | 20 (4.7) | 46 (6.5) | 0.24 |
Female | 9 (5.4) | 15 (4.4) | 0.66 |
Gastrointestinal | 58 (9.7) | 80 (7.6) | 0.14 |
Male | 49 (11.5) | 46 (6.5) | <0.01 |
Female | 9 (5.4) | 34 (10.0) | 0.12 |
Trauma | 54 (9.1) | 86 (8.2) | 0.52 |
Male | 39 (9.1) | 66 (9.3) | 1.0 |
Female | 15 (8.9) | 20 (5.9) | 0.19 |
Alcohol | 140 (23.5) | 256 (24.4) | 0.81 |
Male | 115 (26.9) | 196 (27.6) | 0.84 |
Female | 25 (14.9) | 60 (17.6) | 0.61 |
Others | 183 (30.8) | 315 (30.0) | 0.69 |
Male | 121 (28.3) | 201 (28.3) | 1.0 |
Female | 62 (36.9) | 114 (33.4) | 0.31 |
References
- Kam, A.W.; Chaudhry, S.G.; Gunasekaran, N.; White, A.J.; Vukasovic, M.; Fung, A.T. Fewer presentations to metropolitan emergency departments during the COVID-19 pandemic. Med. J. Aust. 2020, 213, 370–371. [Google Scholar] [CrossRef] [PubMed]
- Wagers, S. Domestic Violence Growing in Wake of Coronavirus Outbreak. The Conversation. Retrieved on 10 April 2020. Available online: https://theconversation.com/domestic-violence-growing-in-wake-of-coronavirus-outbreak-135598 (accessed on 24 April 2022).
- Kolla, B.P.; Oesterle, T.; Gold, M.; Southwick, F.; Rummans, T. Infectious diseases occurring in the context of substance use disorders: A concise review. J. Neurol. Sci. 2020, 411, 116719. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yazdi, K.; Fuchs-Leitner, I.; Rosenleitner, J.; Gerstgrasser, N.W. Impact of the COVID-19 Pandemic on Patients with Alcohol Use Disorder and Associated Risk Factors for Relapse. Front. Psychiatry 2020, 11, 620612. [Google Scholar] [CrossRef] [PubMed]
- Avery, A.R.; Tsang, S.; Seto, E.Y.; Duncan, G.E. Stress, anxiety, and change in alcohol use during the COVID-19 pandemic: Findings among adult twin pairs. Front. Psychiatry 2020, 11, 571084. [Google Scholar] [CrossRef]
- Dubey, S.; Biswas, P.; Ghosh, R.; Chatterjee, S.; Dubey, M.J.; Chatterjee, S.; Lahiri, D.; Lavie, C.J. Psychosocial impact of COVID-19. Diabetes Metab. Syndr. 2020, 14, 779–788. [Google Scholar] [CrossRef]
- Jeffery, M.M.; D’Onofrio, G.; Paek, H.; Platts-Mills, T.F.; Soares, W.E.; Hoppe, J.A.; Genes, N.; Nath, B.; Melnick, E.R. Trends in emergency department visits and hospital admissions in health care systems in 5 states in the first months of the COVID-19 pandemic in the US. JAMA Intern Med. 2020, 180, 1328–1333. [Google Scholar] [CrossRef]
- Boursier, V.; Gioia, F.; Musetti, A.; Schimmenti, A. Facing Loneliness and Anxiety during the COVID-19 Isolation: The Role of Excessive Social Media Use in a Sample of Italian Adults. Front. Psychiatry 2020, 11, 586222. [Google Scholar] [CrossRef]
- Wei, Y.; Zhao, J.; Wong, I.C.; Wan, E.Y.; Taylor, D.M.; Blais, J.E.; Castle, D.J.; Knott, J.C.; Tse, M.L.; Chow, A.T.; et al. Relation of substance use disorders to mortality, accident and emergency department attendances, and hospital admissions: A 13-year population-based cohort study in Hong Kong. Drug Alcohol Depend. 2021, 229, 109119. [Google Scholar] [CrossRef]
- Krawczyk, N.; Eisenberg, M.; Schneider, K.E.; Richards, T.M.; Lyons, B.C.; Jackson, K.; Ferris, L.; Weiner, J.P.; Saloner, B. Predictors of overdose death among high-risk emergency department patients with substance-related encounters: A data linkage cohort study. Ann. Emerg. Med. 2020, 75, 1–12. [Google Scholar] [CrossRef] [Green Version]
- Ibrahim, I.; Jacobs, I.G.; Webb, S.A.; Finn, J. Accuracy of International classification of diseases, 10th revision codes for identifying severe sepsis in patients admitted from the emergency department. Crit. Care Resusc. 2012, 14, 112–118. [Google Scholar]
- Bahorik, A.L.; Satre, D.D.; Kline-Simon, A.H.; Weisner, C.M.; Young-Wolff, K.C.; Campbell, C.I. Alcohol, marijuana, and opioid use disorders: 5-year patterns and characteristics of emergency department encounters. Subst. Abus. 2018, 39, 59–68. [Google Scholar] [CrossRef] [PubMed]
- Marel, C.; Mills, K.L.; Teesson, M. Substance use, mental disorders and COVID-19: A volatile mix. Curr. Opin. Psychiatry 2021, 34, 351–356. [Google Scholar] [CrossRef] [PubMed]
- 2019-nCoV National Incident Room Surveillance Team. 2019-nCoV Acute Respiratory Disease, Australia: Epidemiology Report 1 (Reporting Week 26 January–1 February 2020). Commun. Dis. Intell. 2020, 44, 32050080. [Google Scholar] [CrossRef]
- NSW Government. NSW Health Records and Information Privacy Act 2002 No 71. 2002. Available online: https://legislation.nsw.gov.au/view/html/inforce/current/act-2002-071 (accessed on 24 April 2022).
- McKenzie, S.; Lu, E. Privacy law: NCAT appeal panel taps off on the gold opal card case. Law Soc. NSW J. 2019, 59, 82–83. [Google Scholar]
- Englev, E.; Petersen, K.P. ICH-GCP Guideline: Quality assurance of clinical trials. Status and perspectives. Ugeskr. Laeger. 2003, 165, 1659–1662. [Google Scholar]
- Jacka, B.P.; Phipps, E.; Marshall, B.D. Drug use during a pandemic: Convergent risk of novel coronavirus and invasive bacterial and viral infections among people who use drugs. Int. J. Drug Policy 2020, 83, 102895. [Google Scholar] [CrossRef]
- Alexander, G.C.; Stoller, K.B.; Haffajee, R.L.; Saloner, B. An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. Ann. Intern. Med. 2020, 173, 57–58. [Google Scholar] [CrossRef] [Green Version]
- Wang, Q.Q.; Kaelber, D.C.; Xu, R.; Volkow, N.D. COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States. Mol. Psychiatry 2021, 26, 30–39. [Google Scholar] [CrossRef]
- Coleman, M.; Taran, M.; Cuesta-Briand, B. Responding to rural adversity: A qualitative study of alcohol and other drug service users’ experiences of service response to COVID-19 in Western Australia’s Southwest. Australas. Psychiatry 2022, 30, 74–78. [Google Scholar] [CrossRef]
- Baillargeon, J.; Polychronopoulou, E.; Kuo, Y.F.; Raji, M.A. The Impact of Substance Use Disorder on COVID-19 Outcomes. Psychiatr. Serv. 2021, 72, 578–581. [Google Scholar] [CrossRef]
- Sutherland, K.; Chessman, J.; Zhao, J.; Sara, G.; Shetty, A.; Smith, S.; Went, A.; Dyson, S.; Levesque, J.F. Impact of COVID-19 on healthcare activity in NSW, Australia. Public Health Res. Pract. 2020, 30, 3042030. [Google Scholar] [CrossRef] [PubMed]
- Fuchs-Leitner, I.; Yazdi, K.; Gerstgrasser, N.W.; Rosenleitner, J. Developments in Drug Addiction during COVID-19—An Austrian Perspective Based on a Clinical Sample. Front. Psychiatry 2020, 11, 602033. [Google Scholar] [CrossRef] [PubMed]
- Farhoudian, A.; Baldacchino, A.; Clark, N.; Gerra, G.; Ekhtiari, H.; Dom, G.; Mokri, A.; Sadeghi, M.; Nematollahi, P.; Demasi, M.; et al. COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper. Basic Clin. Neurosci. 2020, 11, 133–150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marsden, J.; Darke, S.; Hall, W.; Hickman, M.; Holmes, J.; Humphreys, K.; Neale, J.; Tucker, J.; West, R. Mitigating and learning from the impact of COVID-19 infection on addictive disorders. Addiction 2020, 115, 1007–1010. [Google Scholar] [CrossRef] [Green Version]
- Mackolil, J.; Mackolil, J. Addressing psychosocial problems associated with the COVID-19 lockdown. Asian J. Psychiatr. 2020, 51, 102156. [Google Scholar] [CrossRef]
- Wakeman, S.E.; Green, T.C.; Rich, J. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat. Med. 2020, 26, 819–820. [Google Scholar] [CrossRef]
- Dunlop, A.; Lokuge, B.; Masters, D.; Sequeira, M.; Saul, P.; Dunlop, G.; Ryan, J.; Hall, M.; Ezard, N.; Haber, P.; et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct. J. 2020, 17, 26. [Google Scholar] [CrossRef]
- Velásquez García, H.A.; Wilton, J.; Smolina, K.; Chong, M.; Rasali, D.; Otterstatter, M.; Rose, C.; Prystajecky, N.; David, S.; Galanis, E.; et al. Mental Health and Substance Use Associated with Hospitalization among People with COVID-19: A Population-Based Cohort Study. Viruses 2021, 13, 2196. [Google Scholar] [CrossRef]
- Brotto, L.A.; Chankasingh, K.; Baaske, A.; Albert, A.; Booth, A.; Kaida, A.; Smith, L.W.; Racey, S.; Gottschlich, A.; Murray, M.C.M.; et al. The influence of sex, gender, age, and ethnicity on psychosocial factors and substance use throughout phases of the COVID-19 pandemic. PLoS ONE 2021, 16, e0259676. [Google Scholar] [CrossRef]
- Martinotti, G.; Alessi, M.C.; Di Natale, C.; Sociali, A.; Ceci, F.; Lucidi, L.; Picutti, E.; Di Carlo, F.; Corbo, M.; Vellante, F.; et al. Psychopathological Burden and Quality of Life in Substance Users during the COVID-19 Lockdown Period in Italy. Front. Psychiatry 2020, 11, 572245. [Google Scholar] [CrossRef]
- Thurber, K.A.; Barrett, E.M.; Agostino, J.; Chamberlain, C.; Ward, J.; Wade, V.; Belfrage, M.; Maddox, R.; Peiris, D.; Walker, J.; et al. Risk of severe illness from COVID-19 among Aboriginal and Torres Strait Islander adults: The construct of ‘vulnerable populations’ obscures the root causes of health inequities. Aust. N. Z. J. Public Health 2021, 45, 658–663. [Google Scholar] [CrossRef] [PubMed]
- COVID-19 National Incident Room Surveillance Team. COVID-19 Australia: Epidemiology Report 33 Fortnightly reporting period ending 17 January 2021. Commun. Dis. Intell. 2021, 45, 32552623. [Google Scholar] [CrossRef]
- Repici, A.; Pace, F.; Gabbiadini, R.; Colombo, M.; Hassan, C.; Dinelli, M.; ITALIAN GI-COVID19 Working Group. Endoscopy units and the coronavirus disease 2019 outbreak: A multicenter experience from Italy. Gastroenterology 2020, 159, 363–366.e3. [Google Scholar] [CrossRef] [PubMed]
- Gadsden, T.; Wilson, G.; Totterdell, J.; Willis, J.; Gupta, A.; Chong, A.; Clarke, A.; Winters, M.; Donahue, K.; Posenelli, S.; et al. Can a continuous quality improvement program create culturally safe emergency departments for Aboriginal people in Australia? A multiple baseline study. BMC Health Serv. Res. 2019, 19, 222. [Google Scholar] [CrossRef]
- Holland, C. Close the Gap 2018-A Ten Year Review: The Closing the Gap Strategy and Recommendations for Reset. 2018. Available online: https://humanrights.gov.au/our-work/aboriginal-and-torres-strait-islander-social-justice/publications/close-gap-10-year-review (accessed on 24 April 2022).
- Willis, J. Closing the gap-2020 marks a new era. Indep. Educ. 2020, 50, 16–17. [Google Scholar]
- Gwynne, K.; Jeffries, T.; Lincoln, M. Improving the efficacy of healthcare services for Aboriginal Australians. Aust. Health Rev. 2019, 43, 314–322. [Google Scholar] [CrossRef]
- Australian Indigenous HealthInfoNet. Overview of Aboriginal and Torres Strait Islander Health Status 2018. Perth: Australian Indigenous HealthInfoNet. 2019. Available online: https://healthinfonet.ecu.edu.au/healthinfonet/getContent.php?linkid=617557&title=Overview+of+Aboriginal+and+Torres+Strait+Islander+health+status+2018&contentid=36501_1 (accessed on 24 April 2022).
- Owen, S.; Carrington, K. Domestic violence (DV) service provision and the architecture of rural life: An Australian case study. J. Rural Stud. 2015, 39, 229–238. [Google Scholar] [CrossRef] [Green Version]
- Ansari, S.; Boyle, A. Emergency department-based interventions for women suffering domestic abuse: A critical literature review. Eur. J. Emerg. Med. 2017, 24, 13–18. [Google Scholar] [CrossRef]
- Haregu, T.; Jorm, A.F.; Paradies, Y.; Leckning, B.; Young, J.T.; Armstrong, G. Discrimination experienced by Aboriginal and Torres Strait Islander males in Australia: Associations with suicidal thoughts and depressive symptoms. Aust. N. Z. J. Psychiatry 2021, in press. [Google Scholar] [CrossRef]
- Mellis, A.M.; Kelly, B.C.; Potenza, M.N.; Hulsey, J.N. Trust in a COVID-19 vaccine among people with substance use disorders. Drug Alcohol Depend. 2021, 220, 108519. [Google Scholar] [CrossRef]
- Dietze, P.M.; Hall, C.; Price, O.; Stewart, A.C.; Crawford, S.; Peacock, A.; Maher, L. COVID-19 vaccine acceptability among people in Australia who inject drugs: Implications for vaccine rollout. Drug Alcohol Rev. 2022, 41, 484–487. [Google Scholar] [CrossRef] [PubMed]
- Masson, C.L.; McCuistian, C.; Straus, E.; Elahi, S.; Chen, M.; Gruber, V.A.; Le, T.; Guydish, J. COVID-19 vaccine trust among clients in a sample of California residential substance use treatment programs. Drug Alcohol Depend. 2021, 225, 108812. [Google Scholar] [CrossRef] [PubMed]
- Blake, D.; Lyons, A. Opioid Substitution Treatment Planning in a Disaster Context: Perspectives from Emergency Management and Health Professionals in Aotearoa/New Zealand. Int. J. Environ. Res. Public Health 2016, 13, 1122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Holland, K.M.; Jones, C.; Vivolo-Kantor, A.M.; Idaikkadar, N.; Zwald, M.; Hoots, B.; Yard, E.; D’Inverno, A.; Swedo, E.; Chen, M.S.; et al. Trends in US emergency department visits for mental health, overdose, and violence outcomes before and during the COVID-19 pandemic. JAMA Psychiatry 2021, 78, 372–379. [Google Scholar] [CrossRef]
- Hawk, K.F.; Vaca, F.E.; D’Onofrio, G. Reducing Fatal Opioid Overdose: Prevention, Treatment and Harm Reduction Strategies. Yale J. Biol. Med. 2015, 88, 235–245. [Google Scholar]
- Runyan, C.W.; Becker, A.; Brandspigel, S.; Barber, C.; Trudeau, A.; Novins, D. Lethal means counseling for parents of youth seeking emergency care for suicidality. West J. Emerg. Med. 2016, 17, 8–14. [Google Scholar] [CrossRef] [Green Version]
- Stone, D.M.; Holland, K.M.; Bartholow, B.N.; Crosby, A.E.; Davis, S.P.; Wilkins, N. Preventing Suicide: A Technical Package of Policies, Programs, and Practices. Atlanta, GA: National Center for Injury Prevention and Control, Centers for Disease Control and Prevention. 2017. Available online: https://www.cdc.gov/violenceprevention/pdf/suicidetechnicalpackage.pdf (accessed on 24 April 2022).
- Centers for Disease Control and Prevention. Evidence-Based Strategies for Preventing Opioid Overdose: What’s Working in the United States. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. 2018. Available online: http://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf (accessed on 24 April 2022).
- Niolon, P.H.; Kearns, M.; Dills, J.; Rambo, K.; Irving, S.; Armstead, T.; Gilbert, L. Preventing Intimate Partner Violence across the Lifespan: A Technical Package of Programs, Policies, and Practices. National Center for Injury Prevention and Control, Centers for Disease Control and Prevention: Atlanta, GA, USA. 2017. Available online: https://www.cdc.gov/violenceprevention/pdf/ipv-technicalpackages.pdf (accessed on 24 April 2022).
- Poorolajal, J.; Haghtalab, T.; Farhadi, M.; Darvishi, N. Substance use disorder and risk of suicidal ideation, suicide attempt and suicide death: A meta-analysis. J. Public Health 2016, 38, e282–e291. [Google Scholar] [CrossRef]
- Yasmin, F.; Najeeb, H.; Asghar, M.S.; Ullah, I.; Islam, S.M.S. Increased COVID-19 infection risk, COVID-19 vaccine inaccessibility, and unacceptability: Worrisome trio for patients with substance abuse disorders. J. Glob. Health 2021, 11, 03106. [Google Scholar] [CrossRef]
Demographic Details | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Male | 450 (1.1) | 745 (2.2) | <0.01 |
Indigenous | 46 (0.1) | 74 (0.2) | <0.01 |
Non-Indigenous | 404 (1.0) | 671 (1.9) | <0.01 |
Female | 215 (0.6) | 416 (1.2) | <0.01 |
Indigenous | 59 (0.2) | 90 (0.3) | 0.01 |
Non-Indigenous | 156 (0.4) | 326 (0.9) | <0.01 |
Category of Admission | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Drug | 19 (0.05) | 16 (0.05) | 0.99 |
Male | 2 (0.01) | 9 (0.03) | <0.05 |
Female | 17 (0.04) | 7 (0.02) | 0.10 |
Infection | 19 (0.05) | 40 (0.12) | <0.01 |
Male | 6 (0.02) | 22 (0.06) | <0.01 |
Female | 13 (0.03) | 18 (0.05) | 0.21 |
Local infection | 6 (0.02) | 19 (0.05) | <0.01 |
Male | 1 (0.003) | 9 (0.03) | <0.01 |
Female | 5 (0.01) | 10 (0.03) | 0.19 |
Gastrointestinal | 16 (0.04) | 16 (0.05) | 0.73 |
Male | 9 (0.02) | 7 (0.02) | 0.99 |
Female | 7 (0.02) | 9 (0.03) | 0.47 |
Trauma | 24 (0.06) | 43 (0.12) | <0.01 |
Male | 6 (0.02) | 4 (0.01) | 0.76 |
Female | 18 (0.05) | 39 (0.11) | <0.01 |
Alcohol | 4 (0.01) | 12 (0.03) | <0.05 |
Male | 4 (0.01) | 6 (0.02) | 0.53 |
Female | 0 (0.0) | 6 (0.02) | <0.05 |
Others | 23 (0.06) | 35 (0.10) | <0.05 |
Male | 19 (0.05) | 25 (0.07) | 0.23 |
Female | 4 (0.01) | 10 (0.03) | 0.10 |
Admission Category | Pre-COVID n (%) | During-COVID n (%) | p Value |
---|---|---|---|
Drug | 48 (0.12) | 135 (0.39) | <0.01 |
Male | 27 (0.07) | 87 (0.25) | <0.01 |
Female | 21 (0.05) | 48 (0.14) | <0.01 |
Infection | 83 (0.21) | 117 (0.34) | <0.01 |
Male | 56 (0.14) | 67 (0.19) | 0.10 |
Female | 27 (0.07) | 50 (0.14) | <0.01 |
Local infection | 29 (0.07) | 61 (0.18) | <0.01 |
Male | 20 (0.05) | 46 (0.13) | <0.01 |
Female | 9 (0.02) | 15 (0.04) | 0.15 |
Gastrointestinal | 58 (0.15) | 80 (0.23) | <0.05 |
Male | 49 (0.12) | 46 (0.13) | 0.76 |
Female | 9 (0.02) | 34 (0.1) | <0.01 |
Trauma | 54 (0.14) | 86 (0.25) | <0.01 |
Male | 39 (0.10) | 66 (0.19) | <0.01 |
Female | 15 (0.04) | 20 (0.06) | 0.24 |
Alcohol | 140 (0.36) | 256 (0.74) | <0.01 |
Male | 115 (0.29) | 196 (0.57) | <0.01 |
Female | 25 (0.06) | 60 (0.17) | <0.01 |
Others | 183 (0.47) | 315 (0.91) | <0.01 |
Male | 121 (0.31) | 201 (0.58) | <0.01 |
Female | 62 (0.16) | 114 (0.33) | <0.01 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jefferies, M.; Rashid, H.; Graham, R.; Read, S.; Banik, G.R.; Lam, T.; Njiomegnie, G.F.; Eslam, M.; Zhao, X.; Ahmed, N.; et al. COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. Vaccines 2022, 10, 889. https://doi.org/10.3390/vaccines10060889
Jefferies M, Rashid H, Graham R, Read S, Banik GR, Lam T, Njiomegnie GF, Eslam M, Zhao X, Ahmed N, et al. COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. Vaccines. 2022; 10(6):889. https://doi.org/10.3390/vaccines10060889
Chicago/Turabian StyleJefferies, Meryem, Harunor Rashid, Robert Graham, Scott Read, Gouri R. Banik, Thao Lam, Gaitan F. Njiomegnie, Mohammed Eslam, Xiaojing Zhao, Nausheen Ahmed, and et al. 2022. "COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out" Vaccines 10, no. 6: 889. https://doi.org/10.3390/vaccines10060889
APA StyleJefferies, M., Rashid, H., Graham, R., Read, S., Banik, G. R., Lam, T., Njiomegnie, G. F., Eslam, M., Zhao, X., Ahmed, N., Douglas, M. W., & George, J. (2022). COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. Vaccines, 10(6), 889. https://doi.org/10.3390/vaccines10060889